RXi licenses RNAi self-delivery technology
This article was originally published in Scrip
Executive Summary
RXi Pharmaceuticals has exercised its option to an exclusive worldwide licence to novel technologies from Advirna to enable in vivo delivery of RNAi therapeutics. Terms of the agreement were not disclosed.